Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SAVIENT PHARMACEUTICALS INC (SVNT)
|
Add to portfolio |
|
|
|
| Price: |
$0.64
| | Metrics |
| OS: |
73.4
|
M
| |
|
|
| Market cap: |
$47
|
M
| |
-1505
|
% ROIC
|
|
Net debt:
|
$437
|
M
| |
|
|
|
EV:
|
$484
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($79.0)
|
M
| |
|
|
|
EBIT
|
($79.4)
|
M
| |
|
|
| EPS |
($1.37)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 18.0 | 9.6 | 4.0 | 3.0 | 3.2 | 14.0 | 47.5 | 49.5 |
| Revenue growth | 88.4% | 137.5% | 36.1% | -6.9% | -77.3% | -70.5% | -4.0% | -20.6% |
| Cost of goods sold | 22.4 | 9.3 | 2.7 | 1.6 | 1.2 | 1.2 | 8.5 | 5.3 |
| Gross profit | -4.4 | 0.3 | 1.4 | 1.4 | 2.0 | 12.8 | 39.0 | 44.2 |
| Gross margin | -24.2% | 2.6% | 33.6% | 45.7% | 63.7% | 91.4% | 82.1% | 89.4% |
| Selling, general and administrative | 88.5 | 90.9 | 25.0 | 30.8 | 35.6 | 31.1 | 34.6 | 36.6 |
| Research and development | 26.2 | 24.8 | 32.4 | 51.7 | 55.5 | 50.9 | 21.4 | 17.0 |
| EBITA | -119.1 | -115.4 | -56.0 | -81.2 | -89.0 | -69.2 | -14.6 | -10.4 |
| EBITA margin | -660.8% | -1206.9% | -1389.9% | -2742.0% | -2798.2% | -493.3% | -30.7% | -21.1% |
| Amortization of intangibles | | | | | | | 2.4 | 4.1 |
| EBIT | -119.1 | -115.4 | -56.0 | -81.2 | -89.0 | -69.2 | -17.0 | -14.5 |
| EBIT margin | -660.8% | -1206.9% | -1389.9% | -2742.0% | -2798.2% | -493.3% | -35.8% | -29.3% |
| Pre-tax income | -118.3 | -128.8 | -73.1 | -92.9 | -88.3 | -61.0 | -1.4 | -0.3 |
| Income taxes | 0.0 | -26.8 | 0.0 | -2.1 | -5.0 | -11.8 | 0.0 | 0.1 |
| Tax rate | 0.0% | 20.8% | 0.0% | 2.2% | 5.7% | 19.4% | | |
| Earnings from continuing ops | -118.3 | -102.0 | -73.1 | -90.9 | -83.2 | -49.2 | -1.5 | -0.5 |
| Earnings from discontinued ops | | | | | | 0.5 | 61.8 | 6.0 |
| Net income | -118.3 | -102.0 | -73.1 | -90.9 | -84.2 | -48.7 | 60.3 | 5.5 |
| Net margin | -656.5% | -1066.7% | -1815.0% | -3069.4% | -2646.0% | -347.0% | 127.0% | 11.1% |
| |
| Diluted EPS | ($1.67) | ($1.46) | ($1.08) | ($1.51) | $4,162,050,000.00 | ($0.94) | ($0.03) | ($0.01) |
| Shares outstanding (diluted) | 70.8 | 70.1 | 67.4 | 60.0 | 0.0 | 52.5 | 58.5 | 60.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|